Although various CAR-T cells targeting different antigens have been developed, CD19-targeted or BCMA-targeted CAR-T cell therapy has proven to be most effective against relapsed/refractory diffuse large B‐cell lymphoma, acute lymphoblastic leukemia, or multiple myeloma, respectively7,8. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.